Get the Stockscreener App
3.245
4.29%
-0.135
Agenus Inc stock is traded at $3.245, with a volume of 312.68K.
It is down -4.29% in the last 24 hours and down -2.27% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$3.38
Open:
$3.4
24h Volume:
312.68K
Relative Volume:
0.49
Market Cap:
$117.28M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0472
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
-3.14%
1M Performance:
-2.27%
6M Performance:
-46.71%
1Y Performance:
-13.96%
1-Day Range:
$3.22
$3.40
1-Week Range:
$3.12
$3.55
52-Week Range:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.245 | 122.16M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.01 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.87 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.87 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.31 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus Strengthens Medical Affairs Infrastructure to Support Growing Authorized Access to Botensilimab–Balstilimab - Oncodaily
Agenus Lands $141M Zydus Partnership to Power BOT+BAL and U.S. Manufacturing Expansion - Oncodaily
Expansion of Global Medical Affairs to Support BOT+BAL Access – Agenus - Oncodaily
Agenus expands medical affairs to support early access to cancer therapy By Investing.com - Investing.com Nigeria
Looking Into Agenus Inc's Recent Short Interest - Benzinga
Agenus expands medical affairs to support early access to cancer therapy - Investing.com
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab - Business Wire
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation - Citeline News & Insights
Agenus Announces First Stakeholder Webcast of 2026 Focused on BOT+BAL Program - Intellectia AI
Agenus to Host First 2026 Stakeholder Webcast - The AI Journal
Agenus signals expanded access and 2026 plans - Traders Union
Agenus Inc. (NASDAQ:AGEN) Sees Significant Increase in Short Interest - MarketBeat
FY2030 Earnings Estimate for Agenus Issued By HC Wainwright - MarketBeat
Agenus (AGEN) Q1 2025 Earnings Call Transcript - AOL.com
Zydus Completes Agenus Deal, Launches US-Based Biologics CDMO Arm Zylidac Bio - Medical Dialogues
Agenus Forms Major Strategic Collaboration with Zydus Lifesciences - TipRanks
Agenus Announces the Closing of $141M Strategic Collaboration with Zydus Group - Oncodaily
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal - Yahoo Finance
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness - 뉴스와이어
Agenus closes strategic collaboration with Zydus Lifesciences By Investing.com - Investing.com Nigeria
Zydus LifeSciences Acquires Biologics Manufacturing Facilities from Agenus - Contract Pharma
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences - BioPharm International
Agenus Falls After $141 Million Zydus Deal Closes - marketscreener.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Zydus Completes Agenus Biologics Facilities Acquisition And Launches U.S. CDMO Unit - Pulse 2.0
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. - StreetInsider
New Zylidac Bio sites help secure U.S. biologic drug supply chains - Stock Titan
Agenus closes strategic collaboration with Zydus Lifesciences - Investing.com
Zydus Lifesciences Completes Agenus Acquisition, Establishes Zylidac Bio LLC for US Biologics Manufacturing - scanx.trade
Cancer combo shows 42% 2yr survival as $141M immunotherapy deal closes - Stock Titan
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer - Investing.com Nigeria
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer By Investing.com - Investing.com South Africa
Agenus Consolidates Financial Leadership With Interim CFO Appointment - TipRanks
Agenus Inc. Appoints Austin Charette as Principal Accounting Officer, Effective January 8, 2026 - marketscreener.com
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas - 뉴스와이어
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
AGEN Stock Price, Forecast & Analysis | AGENUS INC (NASDAQ:AGEN) - Chartmill
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Why Agenus Inc. stock is a must watch in 20252025 Geopolitical Influence & Reliable Price Breakout Alerts - Улправда
What risks investors should watch in Agenus Inc. stockEarnings Overview Summary & Daily Stock Trend Reports - Улправда
Is Agenus Inc. stock attractive for income investorsNew Guidance & Low Risk Entry Point Guides - Улправда
Will Agenus Inc. stock sustain high P E ratiosJuly 2025 Setups & Community Verified Swing Trade Signals - Улправда
Agenus amends Ligand agreement, modifies warrant holder rights - TipRanks
How geopolitical tensions affect Agenus Inc. stockMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
Is Agenus Inc. stock a good choice for value investorsEarnings Forecast Updates & Outstanding Growth Stocks - ulpravda.ru
What valuation multiples suggest for Agenus Inc. stockHead and Shoulders Patterns & Superior Portfolio Investment - ulpravda.ru
Aug Summary: Is Agenus Inc stock attractive for income investorsWeekly Risk Report & Stepwise Entry and Exit Trade Signals - Bộ Nội Vụ
Agenus (AGEN) Q4 2024 Earnings Call Transcript - AOL.com
Agenus (AGEN) Q3 2024 Earnings Call Transcript - The Motley Fool
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.27%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):